CA 125 Elevation: A Descriptive Etiological Study
Introduction: CA 125 (Cancer/Carbohydrate antigen 125) is a surface antigen expressed mostly by the ovarian cancer cells. Hence, it is widely used as a tumour marker for detection and monitoring the progression of such cancers. CA 125 is also expressed by cells of different tissues such as pleu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Pvt. Ltd.
2016-01-01
|
| Series: | National Journal of Laboratory Medicine |
| Subjects: | |
| Online Access: | http://www.njlm.net/articles/PDF/2087/2-%2014984_F(GH)_PFA(Om)_PF2(PVSU).pdf |
| _version_ | 1818985942420029440 |
|---|---|
| author | Shaheena Appan Parambath Charu Yadav Madan Gopal Ranjan Anupama Hegde Ashok Prabhu Poornima Ajay Manjrekar Rukmini Mysore Srikantiah |
| author_facet | Shaheena Appan Parambath Charu Yadav Madan Gopal Ranjan Anupama Hegde Ashok Prabhu Poornima Ajay Manjrekar Rukmini Mysore Srikantiah |
| author_sort | Shaheena Appan Parambath |
| collection | DOAJ |
| description | Introduction: CA 125 (Cancer/Carbohydrate antigen
125) is a surface antigen expressed mostly by the ovarian
cancer cells. Hence, it is widely used as a tumour marker for
detection and monitoring the progression of such cancers.
CA 125 is also expressed by cells of different tissues such
as pleura, pericardium, Mullerian epithelium, peritoneum
etc.
Objective: To identify the different causes leading to
elevation of CA 125 and to estimate the elevation of CA 125
in ovarian and non-ovarian causes.
Materials and Methods: A total of 1800 patients testing for
CA 125 during the time period January 2011 to December
2013in Kasturba Medical College constituent hospitals,
Mangalore were screened. Out of these, OPD patients
and in-patients with CA 125 < 35 U/mL were excluded
and remaining 236 in-patients were included as the study
subjects. Patients were categorized into four groups based
on CA 125 level as Group I(35 – 200 U/mL), Group II (201 –
500 U/mL), Group III (501 – 1000 U/mL) and Group IV (>1000
U/mL). To find association of CA 125 with age, patients were
stratified into 3 groups based on their age as Group A (15-
35 years), Group B (36-55 years) and Group C (≥ 56 years).
Parameters like age, BP, hemoglobin, CA 125,renal profile
and diagnosis of all the patients were evaluated.
Results: Out of 236 patients 54.7% were suffering from
malignant ovarian diseases, 31.3% benign ovarian
disease, 12% non-gynecological diseases and 2% from
gynecological diseases of non-ovarian origin. Mean age
for malignancies was 55 ± 10.6 years for benign diseases
was 34±12.7 years. Incidence of malignancy among the 4
groups (based on CA 125 level) was 34.4%, 48.8%, 68.7%
and 91.6% respectively. Increase in both age and CA 125
levels was highly significant in patients suffering from
ovarian malignancies when compared to those with benign
ovarian diseases (p<0.001).Difference in CA 125 levels was
also statistically significant between malignant and non
gynaecological disorders and between benign ovarian and
non gynaecological disorders as well (p<0.001).
Conclusion: In spite of higher levels of CA 125 in ovarian
carcinoma cases compared to other diagnosis in our data,
results confirm the high false positive rate and non-specificity
associated with CA 125 as a biomarker as it was seen to
increase in numerous other diseases. |
| first_indexed | 2024-12-20T18:42:55Z |
| format | Article |
| id | doaj.art-2a55802dda4d4b218d25f2a25db9729b |
| institution | Directory Open Access Journal |
| issn | 2277-8551 2455-6882 |
| language | English |
| last_indexed | 2024-12-20T18:42:55Z |
| publishDate | 2016-01-01 |
| publisher | JCDR Research and Publications Pvt. Ltd. |
| record_format | Article |
| series | National Journal of Laboratory Medicine |
| spelling | doaj.art-2a55802dda4d4b218d25f2a25db9729b2022-12-21T19:29:46ZengJCDR Research and Publications Pvt. Ltd.National Journal of Laboratory Medicine2277-85512455-68822016-01-01514710.7860/NJLM/2016/14984:2087CA 125 Elevation: A Descriptive Etiological StudyShaheena Appan Parambath0Charu Yadav1Madan Gopal Ranjan2Anupama Hegde3Ashok Prabhu4Poornima Ajay Manjrekar5Rukmini Mysore Srikantiah6PG Tutor, Department of Biochemistry, Centre for Basic Sciences, KMC, Mangalore, India.PG Tutor, Department of Biochemistry, Centre for Basic Sciences, KMC, Mangalore, India.PG Tutor, Department of Biochemistry, Centre for Basic Sciences, KMC, Mangalore, India.Associate Professor, Department of Biochemistry, Centre for Basic Sciences, KMC, Mangalore, India.Associate Professor, Department of Biochemistry, Centre for Basic Sciences, KMC, Mangalore, India.Professor and Head, Department of Biochemistry, Centre for Basic Sciences, KMC, Mangalore, India.Associate Professor, Department of Biochemistry, Centre for Basic Sciences, KMC, Mangalore, India.Introduction: CA 125 (Cancer/Carbohydrate antigen 125) is a surface antigen expressed mostly by the ovarian cancer cells. Hence, it is widely used as a tumour marker for detection and monitoring the progression of such cancers. CA 125 is also expressed by cells of different tissues such as pleura, pericardium, Mullerian epithelium, peritoneum etc. Objective: To identify the different causes leading to elevation of CA 125 and to estimate the elevation of CA 125 in ovarian and non-ovarian causes. Materials and Methods: A total of 1800 patients testing for CA 125 during the time period January 2011 to December 2013in Kasturba Medical College constituent hospitals, Mangalore were screened. Out of these, OPD patients and in-patients with CA 125 < 35 U/mL were excluded and remaining 236 in-patients were included as the study subjects. Patients were categorized into four groups based on CA 125 level as Group I(35 – 200 U/mL), Group II (201 – 500 U/mL), Group III (501 – 1000 U/mL) and Group IV (>1000 U/mL). To find association of CA 125 with age, patients were stratified into 3 groups based on their age as Group A (15- 35 years), Group B (36-55 years) and Group C (≥ 56 years). Parameters like age, BP, hemoglobin, CA 125,renal profile and diagnosis of all the patients were evaluated. Results: Out of 236 patients 54.7% were suffering from malignant ovarian diseases, 31.3% benign ovarian disease, 12% non-gynecological diseases and 2% from gynecological diseases of non-ovarian origin. Mean age for malignancies was 55 ± 10.6 years for benign diseases was 34±12.7 years. Incidence of malignancy among the 4 groups (based on CA 125 level) was 34.4%, 48.8%, 68.7% and 91.6% respectively. Increase in both age and CA 125 levels was highly significant in patients suffering from ovarian malignancies when compared to those with benign ovarian diseases (p<0.001).Difference in CA 125 levels was also statistically significant between malignant and non gynaecological disorders and between benign ovarian and non gynaecological disorders as well (p<0.001). Conclusion: In spite of higher levels of CA 125 in ovarian carcinoma cases compared to other diagnosis in our data, results confirm the high false positive rate and non-specificity associated with CA 125 as a biomarker as it was seen to increase in numerous other diseases.http://www.njlm.net/articles/PDF/2087/2-%2014984_F(GH)_PFA(Om)_PF2(PVSU).pdfantigenbenign ovarian diseasemalignant ovarian disease |
| spellingShingle | Shaheena Appan Parambath Charu Yadav Madan Gopal Ranjan Anupama Hegde Ashok Prabhu Poornima Ajay Manjrekar Rukmini Mysore Srikantiah CA 125 Elevation: A Descriptive Etiological Study National Journal of Laboratory Medicine antigen benign ovarian disease malignant ovarian disease |
| title | CA 125 Elevation: A Descriptive Etiological Study |
| title_full | CA 125 Elevation: A Descriptive Etiological Study |
| title_fullStr | CA 125 Elevation: A Descriptive Etiological Study |
| title_full_unstemmed | CA 125 Elevation: A Descriptive Etiological Study |
| title_short | CA 125 Elevation: A Descriptive Etiological Study |
| title_sort | ca 125 elevation a descriptive etiological study |
| topic | antigen benign ovarian disease malignant ovarian disease |
| url | http://www.njlm.net/articles/PDF/2087/2-%2014984_F(GH)_PFA(Om)_PF2(PVSU).pdf |
| work_keys_str_mv | AT shaheenaappanparambath ca125elevationadescriptiveetiologicalstudy AT charuyadav ca125elevationadescriptiveetiologicalstudy AT madangopalranjan ca125elevationadescriptiveetiologicalstudy AT anupamahegde ca125elevationadescriptiveetiologicalstudy AT ashokprabhu ca125elevationadescriptiveetiologicalstudy AT poornimaajaymanjrekar ca125elevationadescriptiveetiologicalstudy AT rukminimysoresrikantiah ca125elevationadescriptiveetiologicalstudy |